share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  08/29 09:15
Moomoo AI 已提取核心信息
On August 29, 2024, Safety Shot, Inc., a Delaware-based wellness company, announced groundbreaking clinical trial results for its product, Safety Shot, which is designed to reduce blood alcohol content and alleviate symptoms associated with excessive drinking. The double-blind, randomized, placebo-controlled study demonstrated a significant increase in aldehyde dehydrogenase activity and a decrease in acetaldehyde levels, leading to a rapid reduction in blood alcohol content and associated toxins within 30 minutes. The company's COO and Co-Inventor, David Sandler, highlighted the product's unique patented formula and its ability to preemptively address the negative effects of heavy alcohol consumption. Safety Shot, Inc. is expanding its product line, which includes a 12oz drink, 4oz shot, and dry powder stick pack, and is introducing business-to-business sales throughout 2024. The press release also contained forward-looking statements regarding the product's development and commercialization, as well as the company's compliance with laws and potential risks as detailed in its SEC filings.
On August 29, 2024, Safety Shot, Inc., a Delaware-based wellness company, announced groundbreaking clinical trial results for its product, Safety Shot, which is designed to reduce blood alcohol content and alleviate symptoms associated with excessive drinking. The double-blind, randomized, placebo-controlled study demonstrated a significant increase in aldehyde dehydrogenase activity and a decrease in acetaldehyde levels, leading to a rapid reduction in blood alcohol content and associated toxins within 30 minutes. The company's COO and Co-Inventor, David Sandler, highlighted the product's unique patented formula and its ability to preemptively address the negative effects of heavy alcohol consumption. Safety Shot, Inc. is expanding its product line, which includes a 12oz drink, 4oz shot, and dry powder stick pack, and is introducing business-to-business sales throughout 2024. The press release also contained forward-looking statements regarding the product's development and commercialization, as well as the company's compliance with laws and potential risks as detailed in its SEC filings.
2024年8月29日，总部位于特拉华州的健康公司Safety Shot, Inc.宣布其产品Safety Shot在突破性临床试验中取得了重大突破。该产品旨在降低血液中的酒精含量，并缓解过度饮酒所带来的症状。这项双盲、随机、安慰剂对照的研究显示，血液中的醛脱氢酶活性显著增加，乙醛水平下降，从而在30分钟内迅速降低血液中的酒精含量和相关毒素。该公司的首席运营官兼共同发明人David Sandler强调了该产品独特的专利配方及其预防性应对大量饮酒的负面影响的能力。Safety Shot, Inc.将扩大其产品线，包括12盎司饮料、4盎司饮料和干粉棒装，并将在2024年全面推行面向企业的销售。新闻稿还包含了关于该产品的发展和商业化的前瞻性声明，以及该公司根据其SEC文件所详述的法律合规性和潜在风险。
2024年8月29日，总部位于特拉华州的健康公司Safety Shot, Inc.宣布其产品Safety Shot在突破性临床试验中取得了重大突破。该产品旨在降低血液中的酒精含量，并缓解过度饮酒所带来的症状。这项双盲、随机、安慰剂对照的研究显示，血液中的醛脱氢酶活性显著增加，乙醛水平下降，从而在30分钟内迅速降低血液中的酒精含量和相关毒素。该公司的首席运营官兼共同发明人David Sandler强调了该产品独特的专利配方及其预防性应对大量饮酒的负面影响的能力。Safety Shot, Inc.将扩大其产品线，包括12盎司饮料、4盎司饮料和干粉棒装，并将在2024年全面推行面向企业的销售。新闻稿还包含了关于该产品的发展和商业化的前瞻性声明，以及该公司根据其SEC文件所详述的法律合规性和潜在风险。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息